Treatment Options and Management of Functional Dyspepsia
Treatment Options and Management of Functional Dyspepsia
The goal of this article is to provide a narrative review of management options for FD. To accomplish this, a comprehensive search of the published literature using the PubMed database was performed. For Ovid MEDLINE and PubMed (1966 to December 2011) separate searches using the 3 key terms 'functional dyspepsia', 'dyspepsia' and 'non-ulcer dyspepsia' (English language) were combined (using the 'AND' operator) with 'adults', followed by additional search terms as text terms and (where appropriate) MeSH headings including all of the medications and therapies described in the text. Results focused on human trials, English language, adults and full manuscripts; abstracts were included only if the information was felt to be critical to the manuscript. References within studies that met selection criteria were manually searched for other potentially relevant studies. Studies were excluded from analysis for the following reasons: FD was not specifically defined; the study was retrospective in nature; study duration was less than 4 weeks; a placebo group was not included; total sample size <20 subjects; and randomisation did not occur. Although the Rome III criteria for FD now include subcategories of EPS and PDS, with the exception of acotiamide, the treatment section below did not address management changes in these subcategories, since prospective trials comparing symptom responses in these two subgroups are lacking.
Methods
Literature Review
The goal of this article is to provide a narrative review of management options for FD. To accomplish this, a comprehensive search of the published literature using the PubMed database was performed. For Ovid MEDLINE and PubMed (1966 to December 2011) separate searches using the 3 key terms 'functional dyspepsia', 'dyspepsia' and 'non-ulcer dyspepsia' (English language) were combined (using the 'AND' operator) with 'adults', followed by additional search terms as text terms and (where appropriate) MeSH headings including all of the medications and therapies described in the text. Results focused on human trials, English language, adults and full manuscripts; abstracts were included only if the information was felt to be critical to the manuscript. References within studies that met selection criteria were manually searched for other potentially relevant studies. Studies were excluded from analysis for the following reasons: FD was not specifically defined; the study was retrospective in nature; study duration was less than 4 weeks; a placebo group was not included; total sample size <20 subjects; and randomisation did not occur. Although the Rome III criteria for FD now include subcategories of EPS and PDS, with the exception of acotiamide, the treatment section below did not address management changes in these subcategories, since prospective trials comparing symptom responses in these two subgroups are lacking.
